Silo Pharma Inc (SILO)

Silo Pharma Inc. is a developmental-stage biopharmaceutical company listed on NASDAQ under the ticker SILO. The company is focused on creating therapies for underserved medical conditions, including post-traumatic stress disorder, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. Its pipeline includes SPC-15, an intranasal candidate being developed for PTSD and stress-induced anxiety disorders, and SP-26, a time-release ketamine-loaded implant being studied for fibromyalgia and chronic pain relief. Silo Pharma also has two preclinical programs: SPC-14, an intranasal compound for Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis. The company conducts research and development through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. Incorporated in 2010 and based in Sarasota, Florida, the company was previously known as Uppercut Brands, Inc. before adopting its current name in September 2020.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.